ArticleFrontiers in pharmacology2024

GDF-15 is a potential candidate biomarker for an elevated risk of cardiotoxicity in breast cancer patients receiving neoadjuvant dual anti-HER2 therapy.

Chunyu Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.